Sensei Biotherapeutics (NASDAQ:FTH) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Sensei Biotherapeutics (NASDAQ:FTH) from a sell rating to a hold rating in a report released on Saturday.

Several other research firms have also issued reports on FTH. Raymond James Financial initiated coverage on Sensei Biotherapeutics in a research report on Friday, July 31st. They set an “outperform” rating and a $56.00 price target on the stock. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. JonesTrading initiated coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 target price for the company. Finally, Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ FTH opened at $32.00 on Friday. The company’s 50 day moving average price is $27.27. Sensei Biotherapeutics has a 52-week low of $7.45 and a 52-week high of $37.90. The firm has a market capitalization of $826.88 million, a PE ratio of -0.23 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. As a group, research analysts anticipate that Sensei Biotherapeutics will post -13.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brian C. Stephenson bought 5,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were bought at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the purchase, the chief financial officer owned 46,688 shares of the company’s stock, valued at $1,097,168. This represents a 11.99% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was bought at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the purchase, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at $15,101,263.84. The trade was a 0.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 49,494 shares of company stock valued at $1,188,822 over the last three months. Company insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Several hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics during the 2nd quarter valued at about $3,610,000. Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Bank of America Corp DE increased its stake in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics during the first quarter valued at approximately $4,188,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the last quarter. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.